Abstract:
:Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.
journal_name
Neuro Oncoljournal_title
Neuro-oncologyauthors
Suppiah S,Nassiri F,Bi WL,Dunn IF,Hanemann CO,Horbinski CM,Hashizume R,James CD,Mawrin C,Noushmehr H,Perry A,Sahm F,Sloan A,Von Deimling A,Wen PY,Aldape K,Zadeh G,International Consortium on Meningiomas.doi
10.1093/neuonc/noy178subject
Has Abstractpub_date
2019-01-14 00:00:00pages
i4-i17issue
Suppl 1eissn
1522-8517issn
1523-5866pii
5289366journal_volume
21pub_type
杂志文章,评审相关文献
NEURO-ONCOLOGY文献大全abstract:BACKGROUND:While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recu...
journal_title:Neuro-oncology
pub_type: 杂志文章,多中心研究
doi:10.1093/neuonc/nov145
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not068
更新日期:2013-08-01 00:00:00
abstract::Radiotherapeutic doses for malignant gliomas are generally palliative because greater, supposedly curative doses would impart clinically unacceptable damage to nearby vital CNS tissues. To improve radiation treatment for human gliomas, we evaluated microbeam radiation therapy, which utilizes an array of parallel, micr...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/4.1.26
更新日期:2002-01-01 00:00:00
abstract::An increase in the incidence of CNS tumors has been observed in many countries in the last decades. The reality of this trend has been much debated, as it has happened during a period when computer-assisted tomography and MRI have dramatically improved the detection of these tumors. The Gironde CNS Tumor Registry prov...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor120
更新日期:2011-12-01 00:00:00
abstract::Protein kinase C alpha (PKC-alpha) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation. Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice. In this ...
journal_title:Neuro-oncology
pub_type: 临床试验,杂志文章
doi:10.1215/S1152851703000353
更新日期:2005-01-01 00:00:00
abstract:Background:There have been few treatment advances for patients with glioblastoma (GBM) despite increasing scientific understanding of the disease. While factors such as intrinsic tumor biology and drug delivery are challenges to developing efficacious therapies, it is unclear whether the current clinical trial landscap...
journal_title:Neuro-oncology
pub_type: 杂志文章,meta分析
doi:10.1093/neuonc/noy027
更新日期:2018-07-05 00:00:00
abstract:BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...
journal_title:Neuro-oncology
pub_type: 杂志文章,meta分析
doi:10.1093/neuonc/noz013
更新日期:2019-07-11 00:00:00
abstract::Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nox021
更新日期:2017-08-01 00:00:00
abstract::To determine the effectiveness of stereotactic radiosurgery (SRS) treatment to central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL), we analyzed long-term results in VHL patients treated with SRS. Patients were enrolled in a prospective VHL natural history study, undergoing SRS treatment o...
journal_title:Neuro-oncology
pub_type: 临床试验,杂志文章
doi:10.1093/neuonc/nop018
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:The transcription factor homeobox C9 (HOXC9) plays a crucial role in developmental regulatory systems, where it determines the specific positional identities of cells along the anteroposterior axis. The expression of HOXC9 has been found to be dysregulated in some cancers such as lung cancer, breast cancer, ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov281
更新日期:2016-06-01 00:00:00
abstract::As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa154
更新日期:2020-10-14 00:00:00
abstract::Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maint...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-113
更新日期:2009-10-01 00:00:00
abstract::Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by ex...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2007-002
更新日期:2007-07-01 00:00:00
abstract:BACKGROUND:Glioblastomas with a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene have a better prognosis than gliomas with wild-type IDH1. METHODS:Here we compare the IDH1 mutational status in 172 contrast-enhancing glioma patients with the invasion profile generated by a patient-specific mathematical m...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou027
更新日期:2014-06-01 00:00:00
abstract:BACKGROUND:Isocitrate dehydrogenase (IDH) mutation status has emerged as an important prognostic marker in gliomas. Currently, reliable IDH mutation determination requires invasive surgical procedures. The purpose of this study was to develop a highly accurate, MRI-based, voxelwise deep-learning IDH classification netw...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz199
更新日期:2020-03-05 00:00:00
abstract:BACKGROUND:Recent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like c...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not116
更新日期:2013-12-01 00:00:00
abstract::The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor091
更新日期:2011-10-01 00:00:00
abstract:Background:Craniopharyngiomas are neoplasms of the sellar/parasellar region that are classified into adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP) subtypes. Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. BRAF ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noy035
更新日期:2018-07-05 00:00:00
abstract::Allergies and the use of anti-inflammatory medication appear to be associated with reduced glioblastoma risk. However, these observations may merely reflect systemic immunosuppression induced by the tumor. To better understand the effect of this tumor on allergies and inflammation, we used CD133 mRNA expression as an ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nop035
更新日期:2010-04-01 00:00:00
abstract:Background:Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noy108
更新日期:2018-09-03 00:00:00
abstract:BACKGROUND:Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. METHODS:Patients with CNS ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now132
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND:A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou132
更新日期:2014-12-01 00:00:00
abstract:BACKGROUND:Cognitive dysfunction is common among patients with brain tumors and can be associated with the disease and treatment with radiotherapy and chemotherapy. However, little is known about genetic risk factors that may moderate the vulnerability for developing cognitive dysfunction. In this study, we examined th...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now057
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND:To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation. METHODS:A retrospective analysis was performed on 291 patients with GBM. The efficacies of VPA and LE...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not057
更新日期:2013-07-01 00:00:00
abstract::This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noy018
更新日期:2018-04-09 00:00:00
abstract::Although external beam radiation is an essential component to the current standard treatment of primary brain tumors, its application is limited by toxicity at doses more than 80 Gy. Recent studies have suggested that brachytherapy with liposomally encapsulated radionuclides may be of benefit, and we have reported met...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos060
更新日期:2012-04-01 00:00:00
abstract::Stereotactic biopsy is often performed for diagnostic purposes before treating patients whose imaging studies highly suggest glioma. Indications cited for biopsy include diagnosis and/or the "inoperability" of the tumor. This study questions the routine use of stereotactic biopsy in the initial management of gliomas. ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/3.3.193
更新日期:2001-07-01 00:00:00
abstract:BACKGROUND:Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in gli...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov263
更新日期:2016-05-01 00:00:00
abstract:BACKGROUND:Higher-grade meningiomas (HGMs; World Health Organization grades II and III) pose a clinical problem due to high recurrence rates and the absence of effective therapy. Preclinical development of novel therapeutics requires a disease model that recapitulates the genotype and phenotype of patient HGM. Oncolyti...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now031
更新日期:2016-09-01 00:00:00
abstract::Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/now182
更新日期:2016-10-01 00:00:00